QGENQiagen N.V.
Price
-1.2%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, price roughly fair, growth steady, the market undecided.
QIAGEN is a leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA (deoxyribonucleic acid), RNA (ribonucleic acid) and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights.
In the company’s own words · 20-F filed Mar 20, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
For the full year FY2025, revenue was $2.09B (+5.7% year on year) and net income $425M.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
Ranks #2 of 21 by RyuScore